Category Archives: Lung cancer

Loralatinib phase II results

Published on 11-6-18, I believe in conjunction with the FDA approval. 276 ALK+ & ROS1+ patients. But only adverse events were reported for the ROS1 patients The description of the results in the article I found was very confusing. The … Continue reading

Posted in Brain metastases, lorlatinib - Lorbrena by Pfizer, Lung cancer, Potential Treatments, Research | Leave a comment

Patients can live a median of 6.8 years after stage 4 diagnosis

A study of 110 patients at the University of Colorado found that 50% of patients live 6.8 years or longer. These were patients who had access to multiple ALK inhibitors through clinical trials at that research University. That University also … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, brigatinib-Alunbrig from Takeda, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, lorlatinib - Lorbrena by Pfizer, Lung cancer, Research | Leave a comment

Brigatinib vs Crizotinib phase 3 interim results

In September 2018, Takeda reported a pre-designated first interim analysis of a phase 3 trial in the New England Journal of Medicine. The study enrolled 275 ALK inhibitor naive patients. Half got Brigatinib and half got Crizotinib. For Brigatinib: at … Continue reading

Posted in Brain metastases, brigatinib-Alunbrig from Takeda, crizotinib - Xalkori from Pfizer, Lung cancer, Research | Leave a comment

FDA conditionally approves Loralatinib

As of 11-2-2018 the FDA conditionally approved Loralatinib. It’s brand name is Lorbrena. The approval is for Loralatinib treatment for patients: 1) as a third line after crizotinib and one other ALK inhibitor (basically Brigatinib), or 2) as a second line treatment … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, Brain metastases, brigatinib-Alunbrig from Takeda, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, lorlatinib - Lorbrena by Pfizer, Lung cancer, Potential Treatments, Regulatory applications & approvals | Leave a comment

Impact of EML4-ALK Variants on resistance

As of April 20, 2018 Study of 2 groups of patients. Group A = 129 patients, Group B = 577 patients. The most frequent variants were Variant 1 (43%) and Variant 3 (40%). “ALK resistance mutations were significantly more common … Continue reading

Posted in lorlatinib - Lorbrena by Pfizer, Lung cancer, Potential Treatments, Research, Resistance to treatment | Leave a comment

Liquid Biopsy can be used to track evolution of resistance

As of January 23, 2018 and March 29, 2018: Plasma genotyping by Next Generation Sequencing (Liquid Biopsy) can be used to track evolution of resistance to various ALK inhibitors. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5785105/ https://www.ncbi.nlm.nih.gov/pubmed/29599410

Posted in Lung cancer, Research | Leave a comment

FDA approves alectinib (Alecensa) as 1st line treatment

As of November 6, 2017 FDA approves alectinib (Alecensa) as 1st line treatment based on Phase 3 results. The estimated median Progression Free Survival (PFS) for patients taking alectinib was 25.7 months, compared with 10.4 months for those taking crizotinib. The … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, Brain metastases, Lung cancer, Potential Treatments, Regulatory applications & approvals | Leave a comment

Phase 1 & 2 full results for Lorlatinib

As of Oct. 16, 2017 Pfizer presented a Press release associated with a presentation at IASLC on Phase 2 results for 275 patients. All following are for ALK+ patients except where Ros1 is indicated Treatment Naive:  ORR 90%; IC-ORR 75% Prior … Continue reading

Posted in Brain metastases, lorlatinib - Lorbrena by Pfizer, Lung cancer, Potential Treatments, Research, Side Effects | Leave a comment

Great page with very high quality info on AlK & AlK inhibitors

Below is a link to a page that provides comprehensive regularly updated info written by two ALK research oncologists Dr. Alice Shaw and Ben Solomon, Phd (then edited by three people). It is written for an audience of doctors and … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, Brain metastases, brigatinib-Alunbrig from Takeda, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, lorlatinib - Lorbrena by Pfizer, Lung cancer, Potential Treatments | Leave a comment

Roche at ASCO with Alectinib findings

Roche (Genentech) announced on June 6, 2017 at the 2017 ASCO conference that the have results from their first line Phase 3 Global Trial that Alectinib had a median PFS of 25.7 months vs 10.4 months for Crizotinib (over a … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, Brain metastases, crizotinib - Xalkori from Pfizer, Lung cancer, Potential Treatments, Research | Leave a comment